fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Positive results from the phase III C-POST trial for adjuvant treatment with Libtayo (cemiplimab) in cutaneous squamous cell carcinoma after surgery – Regeneron

Written by | 23 Mar 2025

Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically significant and… read more.

FDA approves Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma – Checkpoint Therapeutics

Written by | 3 Jan 2025

Checkpoint Therapeutics, Inc. announced that the FDA has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who… read more.

Nivolumab study supports use of immune checkpoint inhibitors in advanced skin cancer

Written by | 25 Oct 2022

Researchers report that patients with advanced cutaneous squamous cell carcinoma, a skin cancer and one of the most frequent malignancies worldwide, benefit from treatment with the immune checkpoint… read more.

FDA approves expanded label for Keytruda for locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation – Merck Inc.

Written by | 12 Jul 2021

Merck has announced that the FDA has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.